Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

This study has been terminated.
Sponsor:
Collaborator:
Peregrine Pharmaceuticals
Information provided by (Responsible Party):
Michael Lilly, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01335204
First received: April 11, 2011
Last updated: March 20, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)